Thalidomide in multiple myeloma

被引:12
|
作者
García-Sanz, R [1 ]
机构
[1] Univ Hosp Salamanca, Dept Haematol, Salamanca 37007, Spain
关键词
anti-angiogenic drugs; immunomodulatory drugs; lymphoproliferative disorders; monoclonal component; multiple myeloma; plasma cell dyscrasias; thalidomide;
D O I
10.1517/14656566.7.2.195
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple myeloma is an incurable bone marrow cancer, the treatment of which is notoriously difficult. Only modest advances have been achieved using complex polychemotherapeutic regimens, transplant strategies and supportive therapy. In 1999, when new drugs for myeloma were urgently needed, thalidomide was introduced and opened up a completely new line of therapy for the disease. Although the mechanism of action is not yet completely understood, thalidomide has demonstrated efficacy in patients with refractory, relapsed myeloma, even in late-stage cases. This article reviews the current knowledge of thalidomide in myeloma treatment, focusing especially on the possible mechanisms of action, clinical results and adverse events of this drug.
引用
收藏
页码:195 / 213
页数:19
相关论文
共 50 条
  • [1] Thalidomide for multiple myeloma
    Folkman, J
    Rogers, MS
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2389 - 2390
  • [2] Thalidomide in multiple myeloma
    Moehler, T. M.
    Hillengass, J.
    Glasmacher, A.
    Goldschmidt, H.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (06) : 431 - 440
  • [3] Thalidomide in multiple myeloma
    Rajkumar, SV
    ONCOLOGY-NEW YORK, 2000, 14 (12): : 11 - 16
  • [4] Thalidomide in multiple myeloma
    Richardson, P
    Hideshima, T
    Anderson, K
    BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (03) : 115 - 128
  • [5] Thalidomide in multiple myeloma
    Boulos, BM
    Jajeh, A
    Osafo, D
    Tamkus, D
    Berko, E
    Tamakloe, M
    Yim, B
    FASEB JOURNAL, 2005, 19 (04): : A550 - A550
  • [6] Thalidomide maintenance in multiple myeloma
    Jacob P. Laubach
    Paul G. Richardson
    Kenneth C. Anderson
    Nature Reviews Clinical Oncology, 2009, 6 : 565 - 566
  • [7] Thalidomide in multiple myeloma - Reply
    Barlogie, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13): : 975 - 976
  • [8] Thalidomide for multiple myeloma - Reply
    Barlogie, B
    Shaughnessy, J
    Tricot, G
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2390 - 2390
  • [9] Thalidomide and thrombosis in multiple myeloma
    Barbui, T
    Falanga, A
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) : 421 - 422
  • [10] The role of thalidomide in multiple myeloma
    Schwab, Chris
    Jagannath, Sundar
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (01): : 26 - 29